Published in Acta Neurol Scand on August 01, 2007
The Soluble Form of the Cellular Prion Protein Enhances Phagocytic Activity and Cytokine Production by Human Monocytes Via Activation of ERK and NF-κB. Immune Netw (2013) 0.89
Identification of adjacent binding sites for the YY1 and E4BP4 transcription factors in the ovine PrP (Prion) gene promoter. J Biol Chem (2009) 0.81
Detection of anti-glutamate receptor ε2 and anti-N-methyl-D: -aspartate receptor antibodies in a patient with sporadic Creutzfeldt-Jakob disease. J Neurol (2011) 0.78
Sniffing out a function for prion proteins. Nat Neurosci (2009) 0.76
Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy. BMC Genomics (2009) 0.76
Up-regulation of mRNA ventricular PRNP prion protein gene expression in air pollution highly exposed young urbanites: endoplasmic reticulum stress, glucose regulated protein 78, and nanosized particles. Int J Mol Sci (2013) 0.75
Use of canonical discriminant analysis to study signatures of selection in cattle. Genet Sel Evol (2016) 0.75
Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry (1996) 2.30
Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Neurology (2008) 1.78
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76
Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science (1976) 1.76
DNA-triplet repeats and neurologic disease. N Engl J Med (1996) 1.60
Competent patients with advanced states of permanent paralysis have the right to forgo life-sustaining therapy. Neurology (1993) 1.58
Familial opticoacoustic nerve degeneration and polyneuropathy. Neurology (1967) 1.50
Category fluency in mild cognitive impairment: reduced effect of practice in test-retest conditions. Alzheimer Dis Assoc Disord (2004) 1.48
Peripheral neuropathy and starvation after gastric partitioning for morbid obesity. Ann Intern Med (1982) 1.31
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci U S A (1981) 1.28
Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology (1976) 1.27
Markers for gene expression in cultured cells from the nervous system. J Biol Chem (1972) 1.26
Transverse myelitis associated with heroin addiction. JAMA (1968) 1.22
Autosomal dominant cerebellar phenotypes: the genotype has settled the issue. Neurology (1995) 1.21
Effects of practice on category fluency in Alzheimer's disease. Clin Neuropsychol (2001) 1.20
Apoptosis and neurologic disease. Am J Med (2000) 1.17
Mononeuritis multiplex in lepromatous leprosy. Arch Neurol (1968) 1.12
Neurologic involvement in Urbach-Wiethe's disease (lipoid proteinosis). A clinical, ultrastructural, and chemical study. Neurology (1971) 1.07
Platelet APP isoform ratios correlate with declining cognition in AD. Neurology (2000) 1.01
Olivopontocerebellar degeneration. Clinical and ultrastructural abnormalities. Arch Neurol (1974) 1.01
Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol (2012) 1.00
Comparison of the hopkins verbal learning test-revised to the California verbal learning test in Alzheimer's disease. Appl Neuropsychol (2001) 1.00
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
Neurological complications of fibrous dysplasia of the skull. Arch Neurol (1968) 0.99
Joseph's disease: an autosomal dominant neurological disease in the Portuguese of the United States and the Azores Islands. Adv Neurol (1978) 0.97
The natural history of Machado-Joseph disease. An analysis of 138 personally examined cases. Can J Neurol Sci (1984) 0.97
Creatine kinase BB isoenzyme levels by radioimmunoassay in patients with neurological disease. Ann Neurol (1978) 0.97
Glial tumor metastases through a ventriculo-pleural shunt. Resultant massive pleural effusion. Arch Neurol (1968) 0.94
The Machado-Joseph disease locus is different from the spinocerebellar ataxia locus (SCA1). Genomics (1992) 0.94
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol Psychiatry (1999) 0.91
Vasoactive intestinal polypeptide in brain synaptosomes. Lancet (1976) 0.91
Progressive ophthalmoplegia. Report of cases. Arch Neurol (1968) 0.90
Joseph disease: an autosomal dominant motor system degeneration. Adv Neurol (1984) 0.90
Differences in the distribution of poly(A) size classes in individual messenger RNAs from neuroblastoma cells. J Biol Chem (1979) 0.89
Physiology of glia: glial-neuronal interactions. Int Rev Neurobiol (1979) 0.88
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87
Frontal lobe ataxia. Surg Neurol (1995) 0.87
Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma. Mol Pharmacol (1975) 0.86
A radioisotopic, chromatographic microassay for acetyl-coenzyme A synthetase and some preliminary studies on the rat brain enzyme. Biochim Biophys Acta (1973) 0.85
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology (2003) 0.85
Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. J Neurol Sci (1997) 0.84
Induction of adenosine 3',5'-monophosphate binding proteins by N6,O2'-dibutyryladenosine 3',5'-monophosphate in mouse neuroblastoma cells. Analysis by two-dimensional gel electrophoresis. Biochemistry (1979) 0.84
Autosomal dominant progressive syndrome of motor-speech loss without dementia. Neurology (1997) 0.84
Serum antibodies to cytomegalovirus in myasthenia gravis: effects of thymectomy and steroids. Neurology (1978) 0.83
Glutamate and malate dehydrogenase activities in Joseph disease and olivopontocerebellar atrophy. Neurology (1987) 0.83
Machado Joseph disease maps to the same region of chromosome 14 as the spinocerebellar ataxia type 3 locus. J Med Genet (1995) 0.82
Regulation of the synthesis of choline-O-acetyltransferase and thymidylate synthetase in mouse neuroblastoma in cell culture. Proc Natl Acad Sci U S A (1971) 0.82
Specific messenger RNA changes in Joseph disease cerebella. Ann Neurol (1983) 0.82
Quantitation and characterisation of poly(A)-containing messenger RNAs from mouse neuroblastoma cells. Biochim Biophys Acta (1977) 0.81
Furosemide-sensitive K+ channel in glioma cells but not neuroblastoma cells in culture. Biochem Biophys Res Commun (1982) 0.81
Altered thymidine kinase or thymidylate synthetase activities in 5-fluoro deoxyuridine resistant variants of mouse neuroblastoma. J Neurochem (1977) 0.81
Reye's syndrome: isolation of parainfluenza virus. Report of three cases. Arch Neurol (1973) 0.81
Idiopathic polyneuropathy associated with cytotoxic anti-neuroblastoma serum. IgG and IgM immunoglobulin studies. Neurology (1975) 0.81
Hypothermia and persisting capacity to develop fever. Occurrence in a patient with sarcoidosis of the central nervous system. Arch Neurol (1977) 0.81
A comparison of thymidylate synthetase activities from 5-fluorodeoxyuridine sensitive and resistant variants of mouse neuroblastoma. J Neurochem (1975) 0.81
Induction of cyclic AMP-binding proteins by dibutyryl cyclic AMP in mouse neuroblastoma cells. Biochim Biophys Acta (1978) 0.80
Joseph disease and Huntington disease: protein patterns in fibroblasts and brain. Neurology (1981) 0.80
An AP-2 binding sequence within exon 1 of human and porcine choline acetyltransferase genes enhances transcription in neural cells. Neuroscience (1997) 0.80
Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture. Mol Pharmacol (1974) 0.79
Molecular genetics, recombinant DNA techniques, and genetic neurological disease. Ann Neurol (1984) 0.79
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol (2008) 0.79
alpha-L-iduronidase deficiency and possible Hurler-Scheie genetic compound. Clinical, pathologic, and biochemical findings. Neurology (1976) 0.79
Xenon-133 SPECT-determined regional cerebral blood flow in Alzheimer's disease: what is typical? J Neuropsychiatry Clin Neurosci (1993) 0.79
Sleep apnea and hypoventilation syndrome associated with acquired nonprogressive dysautonomia: clinical and pathological studies in a child. Ann Neurol (1981) 0.79
Recombinant DNA and neurologic disease: the coming of a new age. Neurology (1983) 0.78
Comparison of the CERAD and CVLT list-learning tasks in Alzheimer's disease. Clin Neuropsychol (2000) 0.78
Molecular neurogenetics: the genome is settling the issue. JAMA (1997) 0.78
Amplification signals anticipation--less DNA is better. Neurology (1992) 0.78
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease. J Clin Endocrinol Metab (1978) 0.78
Decreased 6-mercaptopurine retention by two resistant variants of mouse neuroblastoma with normal hypoxanthine-guanine-phospho-ribosyltransferase activities. J Pharmacol Exp Ther (1975) 0.78
Machado Joseph disease is not an allele of the spinocerebellar ataxia 2 locus. Hum Genet (1994) 0.77
[Statins for treatment of CNS diseases. Status report from research and clinical practice]. Nervenarzt (2005) 0.76
Erroneous diagnosis corrected after 28 years. Not spinal muscular atrophy with ophthalmoplegia but minicore myopathy. Arch Neurol (1996) 0.76
Urine vapor pattern for olivopontocerebellar degeneration. Clin Biochem (1975) 0.76
Memory loss--when is it Alzheimer disease? JAMA (1998) 0.76
Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation. J Neurol Sci (2001) 0.76
Increased release of an amyloidogenic C-terminal Alzheimer amyloid precursor protein fragment from stressed PC-12 cells. J Neurosci Res (1991) 0.76
Genomic neurology: a new beginning. Arch Neurol (2001) 0.76
The 1990s--decade of the brain: the need for a national priority. Neurology (1990) 0.76
Neurotherapeutics, evidence-based neurology, and clinical equipoise. Arch Neurol (1999) 0.76
Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist (1998) 0.76
Morphological differentiation and proteoglycan synthesis regulate Alzheimer amyloid precursor protein processing in PC-12 and human astrocyte cultures. J Neurosci Res (1992) 0.76
The triumph of linkage analysis. Ann Neurol (1990) 0.75
Defining the neurological basis of the Gulf War syndrome. Arch Neurol (2000) 0.75
Idiopathic acute symmetrical polyradiculoneuritis. The Landry-Guillain-Barré-Strohl syndrome. West J Med (1974) 0.75
Spinocerebellar ataxias and ataxins. N Engl J Med (1995) 0.75
Effect of norepinephrine on glucose metabolism in glioblastoma and neuroblastoma cells in cell culture. Proc Natl Acad Sci U S A (1972) 0.75
Presidential judgment. The twenty-fifth amendment. Arch Neurol (1997) 0.75
An anonymous single copy clone (p1,2-2) from a flow sorted human chromosomes 1 and 2 library (D1S33). Nucleic Acids Res (1987) 0.75
Treatment of cerebral edema. Calif Med (1971) 0.75
Mitochondria in evolution and disease. J Child Neurol (1994) 0.75
Autosomal dominant neurological disorders. Ann Neurol (1978) 0.75
Postscript: criteria for accepting a biochemical defect as primary. Adv Neurol (1978) 0.75
Thermolability in Wernicke's encephalopathy. Arch Neurol (1978) 0.75
CK-BB isoenzyme detected by radioimmunoassay. Ann Neurol (1978) 0.75
Differentiation of neuroblastoma, glioma, and hybrid cells in culture as measured by the synthesis of specific protein species: evidence for neuroblast-glioblast reciprocal genetic regulation. J Neurochem (1978) 0.75
Joseph disease: protein patterns in fibroblasts and brain. Neurology (1979) 0.75
Kinetics of acetylcholine synthesis and hydrolysis in myasthenia gravis. Science (1971) 0.75